Medivir Ab Appoints Pia Baumann As Chief Medical Officer

Appointments

Medivir AB appoints Pia Baumann as chief medical officer

Pharmaceutical company Medivir AB has announced that Pia Baumann has taken the role of chief medical officer. Medivir focuses on the development of innovative cancer treatments in areas of high unmet medical need.

Pia Baumann now takes a role on Medivir’s management team, meaning her responsibilities include the continued clinical development of the candidate drug fostroxacitabine bralpamide (fostrox).

Baumann earned her PhD at the Karolinska Institute and has extensive experience in the drug development sphere, specifically within the cancer field. She has experience of clinical work at Karolinska Hospital as well as having experience at both large pharmaceutical companies and smaller biotech companies.

Recently, Baumann has worked at AstraZeneca as vice president medical with global responsibility for the company’s Tagrisso and Lung Cancer franchise. Prior to this she worked at Takeda, Incyte and ARIAD Pharmaceuticals holding various leading global positions.

Jens Lindberg, chief executive officer at Medivir AB, commented: “I am very pleased that Pia now has taken up the role as chief medical officer. She is joining us at an exciting time, considering we have just communicated that fostrox is now entering the expansion phase (phase 2a) in combination with Lenvima. Her experience in global drug development as well as interaction and cooperation with regulatory authorities will be very important for the continued clinical development of fostrox.”

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

The biotechnology company foghorn therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be replacing Sam Agresta after his retirement on 11 September 2023.

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

The Helmholtz Centre for Infection Research (HZI), Germany, has appointed professor Josef Penninger as scientific director.

Olav Hellebø to join Cytovation’s board of directors

Cytovation, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has appointed Olav Hellebø to its board of directors.

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

Olav Hellebø to join Cytovation’s board of directors

Reacta appoints Kevin Hawkins as new head of regulatory affairs

Simon Sinclair appointed as chief medical officer of Ondine Biomedical

Pharmafocus

Categories

Social Footprints